摘要
目的 探讨非小细胞肺癌（NSCLC）患者血浆D-二聚体水平及其临床意义.方法 采用酶联免疫吸附法（ELISA）检测235例NSCLC患者,其中手术治疗组116例,化学治疗组119例.各组治疗前后与110例健康对照者的血浆D-二聚体水平相比较.随访1年,记录术后、化学治疗后肿瘤复发转移率及NSCLC患者化学治疗后的中位生成时间.结果 NSCLC患者血浆D-二聚体水平为（1.70±0.24）mg/L,显著高于健康对照组的（0.24±0.02） mg/L（P＜0.05）.Ⅲ～Ⅳ期NSCLC患者（化疗组）D-二聚体水平为（2.30±0.32）mg/L,明显高于Ⅰ～Ⅱ期NSCLC患者（手术组）的（0.86±0.36）mg/L（P＜0.05）.化疗组化学治疗前、后血浆D-二聚体的阳性率差异无统计学意义;化学治疗前血浆D-二聚体阳性患者的中位生存时间为8.2个月,显著低于阴性患者的13.6个月（P＜0.05）.结论 NSCLC患者的血浆D-二聚体水平与肿瘤分期有关,可能有助于评估临床疗效及判断预后.
Objective To study the plasma D-dimer level in the patients with non-small cell lung cancer （NSCLC） and its clinical significance.Methods The enzyme-linked immunosorbent assay （ELISA） was adopted to detect the plasma D-dimer level in 235 patients with NSCLC,including the surgical treatment group （116 cases） and the chemotherapy group（119 cases）; the plasma D-dimer levels before and after treatment in each group were compared with those in 1 10 healthy controls.Follow-up lasted for 1 year.The tumor reccurrrence rate and the metastasis rate after operation and chemotherapy,and the median survival time in NSCLC patients after chemotherapy were recorded.Results The plasma D-dimer level was （1.70 ＋0.24）mg/L in the NSCLC patients,which was significantly higher than （0.24-＋ 0.02） mg/L in the healthy controls,the difference was statistically significant （P ＜ 0.05）.The D-dimer level in the stage Ⅲ,Ⅳof the NSCLC patients（chemotherapy group） was （2.30-＋0.32）mg/L,which was significantly higher than （0.86± 0.36） mg/L in the stage Ⅰ,Ⅱ of the NSCLC patients,the difference was statistically significant（P＜0.05）.The positive rate of plasma D-dimer in the chemotherapy group had no statistical difference between before and after chemotherapy; the median survival time was 8.2 months in the patients with D-dimer positve before chemotherapy,which was significantly lower than 13.6 months in the patients with D-dimer negative（P ＜ 0.05）.Conclusion Plasma D-dimer level in NSCLC patients is related with the tumor stage,which may be conducive to evaluate the clinical curative effect and judge the prognosis.
出处
《中国药业》
CAS
2013年第21期82-83,共2页
China Pharmaceuticals
